{
    "clinical_study": {
        "@rank": "48773", 
        "arm_group": {
            "arm_group_label": "Erwinaze / Erwinase", 
            "arm_group_type": "Experimental"
        }, 
        "brief_summary": {
            "textblock": "The purpose of this study is to evaluate the serum asparaginase activity  in subjects ages\n      18 to <40 years with ALL or LBL who have developed a hypersensitivity to native E. coli\n      asparaginase or pegaspargase."
        }, 
        "brief_title": "An Open-Label, Single-Arm, Multicenter Pharmacokinetic Study of Intramuscular Erwinaze\u00ae (Asparaginase Erwinia Chrysanthemi)/Erwinase\u00ae (Crisantaspase)", 
        "condition": "Acute Lymphoblastic Leukemia (ALL)/Lymphoblastic Lymphoma (LBL)", 
        "condition_browse": {
            "mesh_term": [
                "Leukemia", 
                "Leukemia, Lymphoid", 
                "Precursor Cell Lymphoblastic Leukemia-Lymphoma", 
                "Lymphoma", 
                "Lymphoma, Non-Hodgkin"
            ]
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          1. Have a diagnosis of ALL or LBL\n\n          2. Be 18 to <40 years of age at the time of enrollment\n\n          3. Have a documented \u2265 Grade 2 clinical hypersensitivity reaction to native E. coli\n             asparaginase (e.g., Elspar or Kidrolase) or pegaspargase (Oncaspar)\n\n          4. Have the following asparaginase doses remaining in their treatment plan:\n\n               -  At least two (2) consecutive weeks of native E. coli asparaginase treatment OR\n\n               -  At least one (1) dose of pegaspargase (Oncaspar)\n\n          5. Have a direct bilirubin \u2264 Grade 2 (<3.0 mg/dL [52 \u00b5mol/L])\n\n          6. Have amylase and lipase within normal limits (per institutional standards)\n\n          7. Have a serum asparaginase activity below the detectable limit during screening prior\n             to the first dose of study drug (Erwinaze)\n\n          8. Consent to use a medically acceptable method of contraception throughout the entire\n             study period and for 4 weeks after the study is completed. Medically acceptable\n             methods of contraception that may be used by the subject and/or the partner include\n             abstinence, birth control pills or patches, diaphragm and spermicide, condom and\n             vaginal spermicide, surgical sterilization, postmenopausal, vasectomy (>6 months\n             prior to baseline), and progestin implant or injection.\n\n          9. Have signed informed consent\n\n        Exclusion Criteria:\n\n          1. Prior history of \u2265 Grade 3 pancreatitis\n\n          2. Prior history of a major thrombotic event as assessed by the investigator, or any\n             subject with a history of asparaginase-associated serious hemorrhagic or thrombotic\n             event requiring prolonged anticoagulation therapy with agents such as heparin\n\n          3. Prior treatment with Erwinaze\n\n          4. Pregnant or lactating female subjects or female subjects of childbearing potential\n             not willing to use an adequate method of birth control (listed above) for the\n             duration of the study\n\n          5. Subjects with a history of human immunodeficiency virus (HIV) or hepatitis.\n\n          6. Any other condition that would cause a risk (in the investigator's judgment) to\n             subjects if they participate in the trial"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "40 Years", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "30", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "May 21, 2014", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT02150928", 
            "org_study_id": "13-006"
        }, 
        "intervention": {
            "arm_group_label": "Erwinaze / Erwinase", 
            "intervention_name": "Erwinaze\u00ae (Asparaginase Erwinia Chrysanthemi)/Erwinase\u00ae (Crisantaspase)", 
            "intervention_type": "Drug"
        }, 
        "intervention_browse": {
            "mesh_term": "Asparaginase"
        }, 
        "is_fda_regulated": "Yes", 
        "is_section_801": "Yes", 
        "lastchanged_date": "May 27, 2014", 
        "location": {
            "contact": {
                "last_name": "Beverly Alger", 
                "phone": "714-456-6257"
            }, 
            "facility": {
                "address": {
                    "city": "Orange", 
                    "country": "United States", 
                    "state": "California", 
                    "zip": "92868-3201"
                }, 
                "name": "University of California, Irvine"
            }, 
            "investigator": {
                "last_name": "Leonard S Sender, MD", 
                "role": "Principal Investigator"
            }, 
            "status": "Recruiting"
        }, 
        "location_countries": {
            "country": "United States"
        }, 
        "number_of_arms": "1", 
        "official_title": "An Open-Label, Single-Arm, Multicenter Pharmacokinetic Study of Intramuscular Erwinaze\u00ae (Asparaginase Erwinia Chrysanthemi)/Erwinase\u00ae (Crisantaspase) Administered Following Hypersensitivity to E. Coli Asparaginase in Young Adults With Acute Lymphoblastic Leukemia or Lymphoblastic Lymphoma", 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "United States: Food and Drug Administration"
        }, 
        "phase": "Phase 2", 
        "primary_completion_date": {
            "#text": "June 2015", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "measure": "Serum asparaginase activity levels", 
            "safety_issue": "Yes", 
            "time_frame": "48 h postdose 5"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT02150928"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "source": "Jazz Pharmaceuticals", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Jazz Pharmaceuticals", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "May 2014", 
        "study_design": "Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "May 2014"
    }
}